Mesoblast Limited vs Shopify Inc. — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Shopify Inc. trades at $123.25 (market cap $161.53B). The key difference: Shopify Inc. is far larger — about 74.4× Mesoblast Limited's market cap. Which is the better fit depends on your goals.
| MESO | SHOP | |
|---|---|---|
Market Cap | $2.17B | $161.53B |
Sector | Technology | Technology |
52-Week High | $20.96 | $179.01 |
52-Week Low | $12.88 | $95.40 |
Enterprise Value | $2.17B | $155.97B |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
SHOP trades at $125.88, up 1.88% today, with a bullish technical signal from moving averages. The stock shows strong revenue growth, reaching $11.56 billion in 2025, and has turned profitable with a net income margin of 10.77%. Recent news highlights its AI strategy and a Jefferies upgrade to Buy with a $160 target. Cash flow from operations improved to $2.03 billion, though valuation ratios remain elevated.
The outlook is positive, supported by analyst consensus and growth in AI-driven commerce. However, high P/E of 121.14 and competitive pressures from Amazon pose risks. Upside to the $150.08 consensus target depends on execution of AI initiatives and sustained profitability.
Trailing returns across standard periods
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →